Owlstone Medical Enters Collaboration to Advance Early Disease Detection Using Non-Invasive Breath BiopsyNovember 7, 19
Thermo Fisher Scientific Orbitrap GC-MS technology to be integrated into Breath Biopsy to support identification of novel biomarkers for early disease detection
Cambridge, UK, November 07 2019: Owlstone Medical, the global leader in Breath Biopsy® for applications in early disease detection and precision medicine, today announced it has partnered with Thermo Fisher Scientific, the world leader in serving science. The collaboration seeks to advance the application of non-invasive breath sampling to address the challenges of the early detection of disease and the precision medicine delivery of healthcare through the discovery and validation of novel biomarkers.
Under the agreement, both parties will work to integrate the Thermo Scientific™ Q Exactive™ GC Hybrid Quadrupole-Orbitrap™ Mass Spectrometer into Owlstone Medical’s Breath Biopsy platform. An initial project will seek to qualify the mass analyzer for the detection of new biomarkers via a validated discovery and routine analysis project. Upon successful completion, the technology will then become a standard part of Owlstone Medical’s biomarker discovery process, whereby metabolomic studies are conducted on breath samples for internal programs, or on behalf of pharmaceutical or academic clients, to discover novel biomarkers that could translate into research and clinical tests. The work will take place at Owlstone Medical’s Cambridge, UK, Breath Biopsy laboratory.
“There is clearly a growing need for non-invasive diagnostic solutions to support the early detection of disease.” said Morten Bern, senior director marketing, chromatography and mass spectrometry, Thermo Fisher Scientific. “The integration of our Orbitrap GC-MS technology with Owlstone Medical’s Breath Biopsy platform provides a unique basis to improve patient outcomes through the discovery of breath biomarkers and their incorporation into clinical practice.”
Billy Boyle, co-founder and CEO at Owlstone Medical, said: “The GC Orbitrap platform’s ability to detect a wide range of chemicals during both targeted and untargeted analyses without losing selectivity or sensitivity, promises to be of substantial benefit to our Breath Biopsy platform. With a large and rapidly expanding installed base of GC Orbitrap systems, our partnership with Thermo Fisher Scientific represents an exciting opportunity for cross-promotion of the platform and technique, by which the benefits of Breath Biopsy can be broadly realized.”
Further to the scientific and technical expertise, this collaboration will be supported by a joint marketing and customer support effort to ensure the global reach of the Breath Biopsy platform.
This entry was posted in News from Zyme and the companies we work with. Bookmark the permalink.